Calliditas Therapeutics (CALTX)

Stockholm
Currency in SEK
208.00
0.00(0.00%)
Closed·
Showing Calliditas Therapeutics historical data. For real-time data please try another search
Fair Value
Day's Range
206.40208.00
52 wk Range
98.00208.80
Key Statistics
Edit
Bid/Ask
208.00 / 208.00
Prev. Close
208
Open
206.4
Day's Range
206.4-208
52 wk Range
98-208.8
Volume
-
Average Volume (3m)
101.12K
1-Year Change
1.17%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CALTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Calliditas Therapeutics News & Analysis

Show more

Calliditas Therapeutics Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company’s lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. As of September 13, 2024, Calliditas Therapeutics AB (publ) operates as a subsidiary of Asahi Kasei Corporation.

Employees
222
Market
Sweden

Compare CALTX to Peers and Sector

Metrics to compare
CALTX
Peers
Sector
Relationship
P/E Ratio
0.0x−4.8x−0.5x
PEG Ratio
0.00−0.050.00
Price/Book
0.0x4.4x2.6x
Price / LTM Sales
0.0x4.1x3.1x
Upside (Analyst Target)
0.0%0.0%47.8%
Fair Value Upside
Unlock−16.9%6.9%Unlock

Earnings

Latest Release
Feb 20, 2025
EPS / Forecast
-0.88 / 2.16
Revenue / Forecast
559.78M / 687.41M
EPS Revisions
Last 90 days

CALTX Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.